Financial StatusCash and cash equivalents were reported at $217 million, which does not include gross proceeds of $172 million from the January 2025 financing.
Market OpportunityGSIs may represent an estimated $1.8B worldwide market opportunity for desmoid tumors, which are shifting away from surgery and traditional cancer therapies in favor of GSI's.
Pipeline ProgressAll pipeline assets remain on track, with the key catalyst, Ph 3 RINGSIDE trial results, expected in 2H25.